Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer by Geenen, Jill J J, Schellens, Jan H M

Get full text

PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer by Geenen, Jill J. J., Linn, Sabine C., Beijnen, Jos H., Schellens, Jan H. M.

Get full text

Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study by Moore, Kathleen N, Chambers, Setsuko K, Hamilton, Erika P, Chen, Lee-May, Oza, Amit M, Ghamande, Sharad A, Konecny, Gottfried E, Plaxe, Steven C, Spitz, Daniel L, Geenen, Jill J J, Troso-Sandoval, Tiffany A, Cragun, Janiel M, Rodrigo Imedio, Esteban, Kumar, Sanjeev, Mugundu, Ganesh M, Lai, Zhongwu, Chmielecki, Juliann, Jones, Suzanne F, Spigel, David R, Cadoo, Karen A

Get full text

WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study by Embaby, Alaa, Kutzera, Joachim, Geenen, Jill J., Pluim, Dick, Hofland, Ingrid, Sanders, Joyce, Lopez-Yurda, Marta, Beijnen, Jos H., Huitema, Alwin D.R., Witteveen, Petronella O., Steeghs, Neeltje, van Haaften, Gijs, van Vugt, Marcel A.T.M., de Ridder, Jeroen, Opdam, Frans L.

Get full text

A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer by Geenen, Jill J. J., Dackus, Gwen M. H. E., Schouten, Philip C., Pluim, Dick, Marchetti, Serena, Sonke, Gabe S., Jóźwiak, Katarzyna, Huitema, Alwin D. R., Beijnen, Jos H., Schellens, Jan H. M., Linn, Sabine C.

Get full text